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This study describes the construction of a self-response inventory to evaluate the perception
of advantages and disadvantages of the Machado-Joseph disease presymptomatic testing, in
44 individuals at-risk for this disease. The results showed that the reliability of this inven-
tory was satisfactory. Factor analysis revealed a bidimensional structure: perceived advan-
tages (pros) and perceived disadvantages (cons) of presymptomatic testing. Social desirability
was found unrelated to the total scores of our inventory. Additional correlation studies, with
other scales, confirmed the convergent validity of the instrument. These results suggest ade-
quate construct validity. This inventory thus seems to be a proper instrument to assess expec-
tations involved in the decision-making process of Machado-Joseph disease presymptomatic
testing.
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INTRODUCTION
Machado-Joseph Disease and
Presymptomatic Testing
Machado-Joseph disease (MJD) was first de-
scribed in the United States, by Nakano et al. (1972).
1This article is based on the master thesis of Luı´sa Rolim and some
portions were presented at the European Meeting on Psychoso-
cial Aspects of Genetics (June 12–15, 2004) in Munich, Germany.
CGPP, IBMC (JS) is a partner of EuroGentest—Genetic Test-
ing in Europe (www.eurogentest.org) and of PHGEN—Public
Health Genomics Network (www.phgen.nrw.de).
2 Centro de Gene´tica Preditiva e Preventiva (CGPP), Institute for
Molecular and Cell Biology (IBMC), University of Porto, Campo
Alegre, 823, 4150-180, Porto, Portugal.
3 Psychology and Sciences of Education College, University of
Coimbra, Coimbra, Portugal.
4 ICBAS, University of Porto, Porto, Portugal.
5Correspondence should be directed to Luı´sa Rolim, Centro de
Gene´tica Preditiva e Preventiva (CGPP), Institute for Molecular
Although it predominantly affects people of Azorean
ancestry, in Portugal, the U.S.A. and Canada
(Sequeiros, 1995) it has also been described in non-
Portuguese families. Owing, mainly, to the involve-
ment and interest of the International Joseph Dis-
ease Foundation, which organized a large number
of genetic screening sessions, several non-Portuguese
families have been located in Northern America,
coming from Costa Rica, Russia, Italy, France and
China. An English family living in Rhode Island
has also been identified more recently (Coutinho,
1994).
MJD is one of the spino-cerebellar ataxias
(SCAs), also known as SCA3, with an autosomal
dominant inheritance, and is considered a cerebel-
lar ataxia, affecting postural balance and the coordi-
nation of all movements, including gait, speech and
and Cell Biology (IBMC), University of Porto, Campo Alegre,
823, 4150-180, Porto, Portugal; e-mail: lrolim@ufp.pt.
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the fine movements of hands. It is progressive and
appears late in life, at an average age of 40.2 years
(43.7 years for women and 37.3 years for men). The
MJD clinical picture includes other manifestations
such as oculomotor problems and bulging eyes, fas-
ciculations, peripheral muscular atrophies and dys-
tonia (a tendency for abnormal postures and some
torsion movements). There is neither mental dete-
rioration nor loss in sphincter control. To date, un-
fortunately, we know of no clinical interventions to
prevent or delay the appearance of the disease. This
disease is now well known as the most prevalent SCA
worldwide.
MJD is due to the expansion of a CAG re-
peat, similar to Huntington disease (HD), within
the coding region of MJD/ATXN3 gene on chromo-
some 14q32.1 (Kawaguchi et al., 1994). Since 1995,
direct detection of the genetic mutation responsi-
ble for MJD has been possible allowing for reliable
presymptomatic diagnosis (Sequeiros, 1996a).
Preliminary studies have investigated attitudi-
nal, psychosocial, and demographic factors that may,
or may not, predict the decision to be tested for a
late onset neurogenetic disease, such as HD (e.g.,
Bloch et al., 1989; Decruyenaere et al., 1993, 1997;
Evers-Kiebooms and Decruyenaere, 1998; Jacopini
et al., 1992; Meissen et al., 1988; van der Steenstraten
et al., 1994). As outlined by these studies, a host of
socio-demographic (e.g., gender, marital status, ed-
ucational level, socio-economic status) and psycho-
logical (e.g., coping style, ego strength, emotional
well-being, risk perception, perceived severity of the
condition, perceived benefits and costs of the health
action) variables have been identified as influencing
the decision, or at least the intention, to have a pre-
dictive genetic testing.
The domain of genetic testing is an interest-
ing one from a health decision-making viewpoint,
because the behavior under consideration is by defi-
nition a detection behavior, as opposed to a behavior
with a more causal link (either health promoting or
impairing) like diet, exercise, smoking, etc. Thus, ex-
amination of decision-making strategies and predic-
tors, including perceived advantages/disadvantages,
relevant to genetic testing, is of potential interest.
Previous Research on Presymptomatic
Testing for MJD
In order to explore the factors associated with
the decision to undergo presymptomatic testing for
MJD, a number of authors (Pau´l, 1996, 1997; Pau´l
et al., 2000; Rolim, 2000) have been developing psy-
chological evaluation instruments, and exploring po-
tential predictors of genetic testing uptake, such as
certain aspects of personality, attitudes towards mar-
riage, children, adoption and abortion, and the per-
ception of costs and benefits of genetic testing, which
we will explore in detail, as the purpose of our study
was to develop a measure of pros/cons perceptions
about MJD genetic testing.
From the psychological point of view, the ben-
efits of having MJD presymptomatic testing were
found to be a reduction in the degree of uncertainty
(independently of test result) and the possibility for
planning the future with regard to procreation and
the disease itself (Sequeiros, 1995, 1996a). Other ad-
vantages of presymptomatic testing for this disease
have been mentioned, by at-risk individuals, namely
to reduce anxiety (obtain reassurance), inform chil-
dren about the risk of developing the disease or even
the possibility of beginning medical treatment (yet
inexistent) for the disease in order to prevent its de-
velopment and/or delay its course (Rolim, 2000). The
arguments mentioned against presymptomatic test-
ing for MJD were the anticipation of negative con-
sequences (e.g., emotional consequences in the fam-
ily, in the peer group and the affected individual)
from a carrier result, and the individual’s difficulties
in adapting to this outcome.
National Program of Presymptomatic Testing
In Portugal, MJD presymptomatic testing is
offered as part of a program (National Program of
Presymptomatic Testing and Genetic Counseling in
MJD6) to asymptomatic adults who would like to be
informed about their genetic status. Figure 1 shows
the current MJD presymptomatic testing protocol
(Sequeiros, 1996b) implemented both in our centre
(CGPP) and in other regional centers. This protocol
reflects an integrated, multi-disciplinary, multi-
phased process, with several sessions organized
6The National Program of Presymptomatic Testing and Genetic
Counseling in MJD was approved in 1995 and it began being im-
plemented in January 1996. Along this first year, it was promoted
the formation of national centers and the constitution of the re-
spective teams as well as the elaboration of the consultation pro-
tocol. Still in the same year (1996) consultations had their begin-
ning, as defined by the protocol, in four of the six centers. The
balance of 1996 was positive, as this period corresponded to the
implantation of the program and to the definition of its guiding
principles, both in terms of investigation and clinical assistance.
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in this order: a first consultation of neurological
evaluation, followed by a genetic counseling session
and psychological evaluation. Approximately three
weeks later there is a second genetic counseling
session that includes a social evaluation. At this ap-
pointment the consultant can then decide whether to
pursue presymptomatic testing using direct gene
analysis. Results are provided at a third counseling
session if the consultant states he/she would like to
know the results of the testing. Both short- (three
weeks post disclosure) and long-term psychological
follow-up (at six and twelve months) are offered
to all participants, who voluntarily choose to par-
ticipate. This protocol is flexible and tailored to
the needs of the consultant and can be used as a
model for other genetic diseases (e.g., familial amy-
loid polyneuropathy of type I, FAP-I). Continued
psychosocial follow-up evaluation is offered at six
months and annual neurological evaluations are
recommended every year for those who test gene
positive.
The goal of this program is to provide educa-
tion and counseling to at-risk individuals so as to
help them decide whether testing is the best deci-
sion for them at this time point and also to ensure
that they are prepared for the outcome of their de-
cision. Specifically, the psychologist’s action includes
the comprehension and evaluation of motivation,
needs and psychological reactions of consultants and
their relatives, as well as the promotion of their emo-
tional expression, so that they can make informed
and thoughtful decisions about presymptomatic test-
ing and many life related areas.
The National Program of Presymptomatic Test-
ing and Genetic Counseling in MJD also includes
a number of psychological research goals, namely
to identify the possible psychosocial predictors of
adherence (acceptance/rejection) to testing, to im-
prove psychological evaluation protocols and to de-
velop efficient psychological intervention strategies,
aimed at preventing emotional disturbances caused
by the genetic result. Therefore, it is important to
develop instruments for psychological evaluation of
individuals interested in presymptomatic testing in
order to “foresee situations of psychosocial risk and
the underlying difficulties in subjects who are look-
ing for a service of medical genetics” (Pau´l, 1997,
p. 248). The purpose of this paper is to present the
development of a measure, the Perceived Advan-
tages and Disadvantages of Presymptomatic Testing
Inventory (PADI), intended to assess the subjective
dimensions (expectations) of the decision-making
Enrolment for the program and consultation appointment
(written information about MJD, genetics and presymptomatic test) 
1st SESSION of Genetic Counseling
1. Information about the disease 
2. Neurological examination 
3. Psychological evaluation 
(anamnesis and questionnaires) 
(3 weeks) 
 
2nd SESSION of Genetic Counseling 
1. Pre-test counseling 
2. Preparation for communicating presymptomatic test results 
(information kept, doubts, motivations) 
3. Social evaluation 
4. Informed consent form 
5. Blood drawning 
(1 to 3 weeks) 
DISCLOSURE OF THE TEST RESULT 
(2 to 3 weeks) 
 
1st Psychological Follow-Up Session 
1. Evaluation of the results impact 
2. Psychological evaluation 
(6 months) 
2nd Psychological Follow-Up Session 
1. Social intervention 
2. Psychological evaluation 
(1 year) 
3rd Psychological Follow-Up Session 
1. Neurological examination 
2. Psychological evaluation 
3. Appointment of new psychological support consultation 
 (if necessary) 
Fig. 1. Consultation protocol of the National Program of
Presymptomatic Testing and Genetic Counseling in Machado-
Joseph disease (adapted from Sequeiros, 1996b, p. 133).
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process, about the MJD presymptomatic testing, and
the evaluative dimension of perceived benefits and
harms that people at genetic risk relate to presymp-
tomatic diagnosis.
Theoretical Basis of the Perceived Advantages and
Disadvantages of Presymptomatic Testing Inventory
In the development of the PADI we first con-
sidered how presymptomatic testing is experienced.
Presymptomatic test for autosomic dominant dis-
eases, like MJD or HD, may be experienced as a
meaningful life event (Hayden et al., 1988), due to
the set of decisional dilemmas, which individuals at
genetic risk must face (Fleming and Lopes, 2000;
Motulsky, 1994). It is almost certain that an early de-
tection of heterozygous condition can cause, in peo-
ple who are uncertain about the possible inheritance
of a molecular mutation, complex decision-making
problems (Evers-Kiebooms et al., 1989; Salkovskis
et al., 1999; Taylor, 2002) that are influenced by multi-
ple psychological and social aspects (Bird, 1999; Pau´l,
1997). Therefore, the study of decision-making pro-
cess, in genetic contexts, and the factors that con-
tribute to individual decision taking, seems to be an
important contribution to modern psychological re-
search (Lerman et al., 2002) and support. These types
of studies are important in the area of genetics, as the
decision to screen is the pivotal decision point in this
approach.
The process of decision-making, in situations
that involve the risk of developing a genetic dis-
ease, may be perceived as a cognitive activity, which
is mediated by emotional answers (e.g., concern,
fear, anxiety) and this way not entirely rational
(Timmermans and Henneman, 2002). In the devel-
opment of this measure we focused on both the
cognitive component, which characterizes most de-
cisions, and the role-played by emotions and their
importance for decision-making in situations of un-
certainty. To help understand the cognitive and emo-
tional components we utilized the Decisional Con-
flict Theory, the Health Belief Model, and the Trans-
theoretical Model of Behavioral Change.
Decisional Conflict Theory by Janis and Mann
(1977) proposes that stress interferes with the ability
to consider the salient features of a situation and to
deliberate carefully about the pros and cons of alter-
native options.
The Health Belief Model (HBM) (Rosenstock,
1974) is a decisional model of cognitive orienta-
tion. This model was developed to integrate differ-
ent health beliefs and to predict health behaviors or
intentions. The model rest on the premises that in-
dividuals are rational information processors (for ex-
ample, the HBM assumes that the individual weighs
up the pros and cons of a behavior, assesses the se-
riousness of a potentially dangerous illness and then
decides how to act), and that decisions are based on
beliefs, so the discernment of these beliefs can con-
tribute to the prediction of future health behavior
(Ogden, 2004). The HBM was used, in our study,
as the foundation and theoretical framework for the
constructs and items comprising the measure we de-
veloped. According to the HBM, the actions towards
health (or the motivation to look for medical care)
will depend on the subjective meaning attributed to
the disease, on the perceived efficiency and on the
perceived costs of medical procedure. The higher the
perceived susceptibility and the perceived severity
of the disease, the higher the health threat and thus
the individual will engage, more likely, in health be-
haviors. Further, the likelihood of engaging in this
behavior will depend on the extent to which the in-
dividual believes that the action yields benefits (in
reducing susceptibility and/or the severity of the con-
dition), which outweigh the barriers. This model may
be described as an integrating approach to constructs
of cognitive kind (perceived susceptibility and per-
ceived seriousness of the disease) and of motivational
kind (balance of costs and benefits), related to the en-
hancement of health promoting actions.
The Transtheoretical Model (TTM) of behav-
ioral change (Prochaska and DiClemente, 1983),
which posits that different processes of change are
useful at different stages of change (precontempla-
tion, contemplation, preparation, action and main-
tenance), was also considered in the development
of the measure. The TTM incorporates intermediate
outcome variables, which predict progress across the
stages of change (Norman et al., 2004; Velicer et al.,
1995): the pros and cons of change from decisional
balance theory (Janis and Mann, 1977).
It has been suggested that decision-making in-
volves the implicit weighing up of those advan-
tages and disadvantages of possible options, con-
sidered relevant at the time the decision is made
(Salkovskis et al., 1999). Harrison et al. (1992),
Hillner (1996), and others, have focused on the per-
ception of costs/benefits in the enhancement of be-
havior related to health.
The evaluative and motivational dimension can
be considered relevant for taking an option towards
MJD presymptomatic diagnosis (Pau´l et al., 2000)
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and prenatal diagnosis (Andrade et al., 1998), in the
overall context of genetic counseling and psycholog-
ical support.
Reasons for the Construction of the Inventory
Bearing in mind the decision-making theory
and research (Janis and Mann, 1977; Rosenstock,
1974; Salkovskis et al., 1999) and that there are not
empirical studies about the analysis of the bino-
mial equation pros/cons or any instrument to evalu-
ate that attitudinal component (cognitive-evaluative-
motivational), as far as MJD presymptomatic testing
is concerned, we decided to construct and study the
psychometric qualities of a self-rating instrument on
the subjective expectations of people at genetic risk
for MJD facing presymptomatic testing.
The measure of the perceived advantages and
disadvantages, constructs derived from the HBM,
was developed to assess the decisional consideration
process related to MJD presymptomatic testing. De-
cisional consideration can be theoretically defined
as the “extent to which a person values or priori-
tizes the positive and negative aspects of a particu-
lar behavior” (Vernon et al., 1999, p. 354). In other
words, we assess people’s cognitive appraisal of the
positive (pros) and negative (cons) aspects of do-
ing MJD genetic test. By focusing on this specific
disorder and on the subject’s perceptions about ge-
netic testing, we think we can improve our under-
standing about decision-making for genetic screening
behaviors.
METHODS
Sample
The study subjects belong to genetically iden-
tified families with MJD and whose relatives at-
tended Portuguese medical centers in Porto, Coim-
bra, Santare´m as well as Angra do Heroı´smo in
Azores. Study subjects were identified through physi-
cian referral and personally contacted, by the first
author of this study (LR), who has explained them
the purposes of the investigation and invited them to
participate. All individuals agreed to take part in the
study. Our study was approved by the institutional
ethics committees.
The total sample included 44 individuals (23
women and 21 men) at genetic risk for MJD, non-
symptomatic, aged between 18 and 61 years (aver-
age age: 34.57 ± 11.19 years), 70.5% of them were
married, 50.4% had, at least, one child, 59.1% had
6 to 9 schooling years of education, 25% had less
than 5 schooling years and 15.9% had completed high
school or had a University degree.
Measurement Development
Semistructured Interviews
In the development and study of the measure,
we first completed semistructured interviews. The in-
terviews were developed by LR and JAZC, in or-
der to obtain socio-demographic information and to
monitor self-response questionnaires. The subjects
were invited to read an introductory letter explain-
ing the nature and purpose of the study and to fill in a
consent form for participation. After obtaining writ-
ten informed consent, we completed a registration
sheet containing items assessing socio-demographic
data and several open-ended questions addressing
family history of the disease, knowledge and expe-
rience about the disease, genetic risk and presymp-
tomatic testing (these information will be presented
elsewhere). Next, participants were asked to fill in
the questionnaires (described below); the PADI was
the last one to be presented.
The interviews were conducted by LR, either in
the medical center or in the subjects home. The mean
duration of the interviews was 45 to 60 min. All the
subjects interviewed stated they were interested in
doing the presymptomatic testing for MJD. As they
were interviewed in a previous phase to their possi-
ble participation in the presymptomatic testing pro-
gram, these individuals will be acknowledged, in the
present study, as candidates to the program.
Socio-Demographic Variables
The 4 defined age groups were: 1 [18–23
Years]; 2 [24–29 Years]; 3 [30–39 Years]; 4 ≥ 40
years. Marital status was categorized into two
groups: 1—Single/Separated/Divorced/Widower and
2—Married/Common Law. Number of children was
divided into: 0—Without children and 1—One or
more children. The considered educational levels
were: 1— ≤ 5 years; 2—6 to 9 years (basic schools);
3—10 to 12 years (secondary schools); 4—over 12
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Table I. Perceived Advantages and Disadvantages of the MJD
Presymptomatic Testing
Advantages Disadvantages
– Reducing the individual
uncertainty
– Perceived incapability of
personal adaptation to the
test result
– Reducing the individual
anxiety (reassurance)
– Perceived negative
consequences coming up
from knowing a carrier result:
– Getting certainty about
whether he/she will develop
the disease
– Increased anxiety and fear
about the future
– Getting certainty about the
chances of passing the
disease on to the offspring
– Anxiety among family
members
– Planning the future – Negative effects on
relationships with others in
the family
– Informing children about
their genetic risk
– Hipervigilance and worry
about minor symptoms
– Beginning possible medical
action
– Concerns about insurability
and discrimination (life,
health, disability)
– No cure for the disease
years (post-secondary education/degree, BSc, college
graduation, Master Degree, PhD).
Item Development for the Perceived Advantages and
Disadvantages of Presymptomatic Testing Inventory
The relevant variable for this study is related to
the cognitive-motivational dimension of attitudes to
MJD presymptomatic testing, more precisely to the
costs and benefits perceived by the individuals at ge-
netic risk. The Perceived Advantages and Disadvan-
tages of Presymptomatic Testing Inventory (PADI)
items identification was determined by:
1. The spontaneous pointing out of reasons
for doing presymptomatic testing by the
first participants in the National Program of
Pre-Symptomatic Testing and Genetic Coun-
seling in MJD, during the pre-screening in-
terview of psychological evaluation included
in the program protocol. Table I summa-
rize the reasons for (pros) and against (cons)
pre-symptomatic testing, spontaneously en-
hanced by at-risk individuals for MJD;
2. The experience obtained with the adminis-
tration of the Presymptomatic Testing Ac-
ceptance Scale—PTAS (Pau´l, 1997). We
have concluded that there was a need to use
a specific instrument to evaluate the dimen-
sion of costs and benefits, to focus on com-
pletely forgotten aspects in PTAS (items 2,
4, 6, 7, 8, 9, 12, 13, 14, 15 and 16 of PADI; cf.
Appendix), and to write items with a simpler
and less dubious interpretation;
3. Comprehensive literature review concerning
the motivation for doing the presymptomatic
diagnosis of HD (e.g., Bloch et al., 1989;
Craufurd et al., 1989; Decruyenaere et al.,
1993, 1997; Evers-Kiebooms, 1989; Evers-
Kiebooms et al., 1989; Jacopini et al., 1992;
Meissen et al., 1988; Tyler and Harper, 1983;
van der Steenstraten et al., 1994);
4. The awareness of the experience with the
construction and administration of a scale
evaluating the expectations related to the
decision-making about pre-natal diagnosis—
the Perceived Costs and Benefits of Pre-
Natal Diagnosis Scale (Andrade et al., 1998).
Considering these pieces of information, we
have made a list of benefits (arguments for the
presymptomatic diagnosis) and of costs (arguments
against) of doing MJD presymptomatic testing. The
statements were then reviewed by health profession-
als and further refined in a small sample of individu-
als at-risk for MJD. During the PADI administration,
people were invited to reflect, to make comments on
the formulation and ordering of the items, to point
out their difficulties in understanding and to suggest
other aspects not observed in this inventory. These
comments were taken into account in the analysis
and selection of items to form the latter version of the
PADI. Given the absence of any difficulty in under-
standing or answering the questions, all items were
retained at this point.
This inventory is composed, in its original ver-
sion, by a pool of 16 attitudinal items (see Appendix),
addressing reasons as to why a subject would decide
to pursue or decline MJD presymptomatic testing.
The scoring of the answers obey to a dichotomic7
structure (YES/NO), so that whenever the subject
7This classifying system is simple, objective and more accessible
(Nunnally, 1978) for the majority of individuals, who are thus not
faced with the difficulty of having to choose between too close an-
swering (e.g., I completely agree and agree; I completely disagree
and disagree). On the other hand, in Likert scales, the answers
do not always express the true attitude of individuals, since many
of them are led to answer the items in systematically extreme or
neutral ways (Simo˜es, 1987).
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agrees with the reason a point is given and whenever
he/she disagrees with the pointed out reason he/she
gets zero points.
The items are divided into 8 reasons for (ad-
vantages/pros) and 8 reasons against (disadvan-
tages/cons) the presymptomatic testing. Similar to
Vernon et al. (1999) and Ho et al. (2003), we exam-
ined the pros and cons separately and produced a
general score (pros minus cons) representing the de-
cisional balance or trade-off between the perceived
advantages and disadvantages of doing presymp-
tomatic testing. Higher scores indicate that the sub-
ject tends to emphasize the advantages (gains) of
screening and lower scores imply that harms (neg-
ative consequences) are considered more impor-
tant than benefits in the decisional consideration
process.
The option for the bipolar conception of PADI
(this is for the separation of reasons into pros and
cons) is based on the assumption that people are
guided, in more or less rational terms, in the de-
cisions they make, by balancing benefits and costs
of each of the existing alternatives (Andrade et al.,
1998). The list of reasons we generated include per-
sonal, familial and social areas. We believe these as-
pects are considered throughout the process of the
presymptomatic testing from decision-making, test-
ing, waiting for the result, and finally learning the test
outcome.
Reliability and Validity of the PADI
The methodological approach to the construc-
tion of the PADI involved four main steps labeled:
(1st) reliability study; (2nd) factorial validity study;
(3rd) sensitiveness to differences of gender, age
and educational level study; (4th) construct validity
studies.
This last section included the study of social
desirability association with PADI scores, for what
we have used the Social Desirability Scale (SDS;
Crowne and Marlowe, 1960), and the study of the
PADI convergent validity, by means of correla-
tion studies with the Attitudes towards Doctors and
Medicine Questionnaire (ADMQ; Marteau, 1990),
and with the Perceived Emotional Burden Related
to the Genetic Disease Scale (PEBGDS; Zagalo-
Cardoso, 1995). These studies were complemented
by a correlation study between PADI and the
Predictive Testing Acceptance Scale (PTAS; Pau´l,
1996).
Social Desirability Scale
The Social Desirability Scale (SDS; Crowne and
Marlowe, 1960), adapted by Simo˜es and Lima (1992)
and used by Andrade (1997), in the context of genetic
counseling, with individuals of the Portuguese pop-
ulation, is composed of 24 items, which correspond
to culturally approved behaviors. It is a scale with
a dichotomic format of true/false answers; score 1 is
attributed when the answer reflects social desirabil-
ity (i.e., the tendency to give answers from which a
greater social approval may result) and score 0 when-
ever this indicator is omitted. The scale internal con-
sistency has proved to be satisfactory, according to
the Kuder-Richardson (K-R) coefficient (.73).
Our aim was to check the influence of social de-
sirability on PADI results and, consequently, on their
construct validity, supposing that the latter will be the
greater, the less guided by a wish of social approval
the answers are.
Attitudes Towards Doctors
and Medicine Questionnaire
Attitudes towards Doctors and Medicine Ques-
tionnaire (ADMQ; Marteau, 1990), in its Portuguese
version (Andrade, 1997), is characterized by a sys-
tem of multiple scoring, of the Likert type, and
is composed of 17 items, selected in relation to
their discriminatory power and metrical characteris-
tics, while having a reasonable internal consistency,
as revealed by the obtained alpha coefficient (.73).
This questionnaire was develop to evaluate the at-
titudes facing doctors’ efficiency in the promotion
of health and it is composed of 2 factors: Factor
1—Negative Attitudes towards Doctors and Medicine
and Factor 2—Positive Attitudes towards Doctors and
Medicine.
In the same way as Andrade (1997), we have
chosen to use, in our research, only the ADMQ to-
tal, due to the fact that the two sub-scales do not
present a structure similar to the original version of
the scale and are a little less consistent than the global
scale.
We hope to find support for the PADI conver-
gent validity, owing to the affinity between the at-
titudinal objects evaluated by this inventory and by
ADMQ: the one of the first scale specifically men-
tions a new health service that allows MJD presymp-
tomatic diagnosis; the one of the second scale is more
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generic and is directed to a macroscopic perspective
of the health care and its agents.
Perceived Emotional Burden Related
to the Genetic Disease Scale
The Perceived Emotional Burden Related to the
Genetic Disease Scale (PEBGDS; Zagalo-Cardoso,
1995) is composed of 24 items. The answers are
scored under the Likert type, with a scoring from 1
to 5, and the total score can range from 24 to 120, the
higher scores indicating greater perceived emotional
burden. The scale has got satisfactory internal con-
sistency (α= .78) and possesses satisfactory construct
validity, because it can differentiate known groups
(e.g., diseases with diverse clinical severity).
PADI is specifically directed to the evaluation of
the arguments for and arguments against presymp-
tomatic testing for a late onset incurable disease. The
second factor of the inventory (perceived barriers)
reflects, namely, the personal and familial burden im-
posed by that plan of action. Based on the struc-
tural affinity between PADI and PEBGDS, and on
empirical data (Zagalo-Cardoso, 1995), we hypothe-
sized that there will be a significant association be-
tween the perception of the burden related to the
genetic disease and each of the PADI dimensions
(perceived advantages and perceived disadvantages
of MJD presymptomatic testing).
Consequently, it is perfectly acceptable that PE-
BGDS may be used to evaluate certain aspects of
PADI’s convergent validity.
Predictive Testing Acceptance Scale
The Predictive Testing Acceptance Scale
(PTAS; Pau´l, 1996) is a one-dimensional (pointing
out the predictive testing acceptance) self-evaluation
scale, of the Likert type. It is composed of 24 items
and has a decreasing classifying system, from 4
to 1, according to the signaled option: completely
agree, agree, disagree and completely disagree. The
factorial analysis in main components, followed by
a Varimax type rotation, has revealed 3 factors:
Factor 1 (F1)—Fears towards the Presymptomatic
Test; Factor 2 (F2)—Planning the Future; Factor
3 (F3)—Reducing Uncertainty. As a whole, the
three defined dimensions explain 37% of the total
variance; in what concerns the specific variances,
Factor 1 explain 15.7%, Factor 2—12% and Factor
3—9.3%. The internal consistency of the three sub-
scales, determined by Cronbach alpha coefficients,
was .38 to the third sub-scale, a value which contrasts
with the homogeneity of the items belonging to
the first two sub-scales: α1 = .60 e α2 = .53. In this
study, we will use a version of PTAS reviewed and
updated, in terms of psychometric qualities (Rolim
and Zagalo-Cardoso, in press), composed of 18 items
(without items 1, 7, 13, 17, 22 and 23 of the original
version), whose Cronbach alpha coefficients have
proved to be more satisfying than the previous ones:
scale (α= .66) and sub-scales, respectively, α1 = .85,
α2 = .76 and α3 = .60.
Statistical Analysis
Means, standard deviations, and frequencies
were generated to describe the data and ensure suit-
ability for parametric statistical analysis. χ2 tests were
performed to determine whether there were signif-
icant differences between frequencies of answers to
PADI items. Pearson product-moment correlations,
K-R coefficients and even-odd correlations were
computed to evaluate the internal consistency of the
PADI. Factorial analyses were conducted to examine
the underlying factor structure of PADI. Eigenvalues
>1.5 and factor loadings >.30 were sought. Between-
participants t tests and bivariate correlations were
computed to test sensitiveness of PADI to differ-
ences of gender, age and educational level, and to de-
termine the effects of social desirability. A p value of
.05 was used for all statistical tests, as the threshold
for statistical significance.
Next we’ll describe the results obtained in each
of the above-mentioned stages.
RESULTS
Descriptive Statistics of the PADI Items
Table II shows some descriptive data about
means, standard deviations and frequencies (per-
centages) of item scores. As it is possible to ob-
serve, the means have varied between .386 (item
3) and .932 (item 10), and the standard deviations
have varied between a minimum of .255 (item 10)
and a maximum of .506 (item 1). Item 1 presents
a balanced distribution of the answers’ frequencies
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Table II. Means, Standard Deviations and Frequencies (Per-
centages) of Item Scores (N = 44)
Items Means
Standard
deviations Yes No
1 .500 .506 50.0 50.0
2 .520 .505 52.3 47.7
3 .864 .347 86.4 13.6
4 .386 .493 38.6 61.4
5 .705 .462 70.5 29.5
6 .450 .504 45.5 54.5
7 .520 .505 52.3 47.7
8 .450 .504 45.5 54.5
9 .640 .487 63.6 36.4
10 .932 .255 93.2 6.8
11 .610 .493 61.4 38.6
12 .750 .438 75.0 25.0
13 .550 .504 54.5 45.5
14 .820 .390 81.8 18.2
15 .550 .504 54.5 45.5
16 .660 .479 65.9 34.1
PADI statistics (N = 44) Mean % answers
Yes No
M = 9.910 SD = 2.361 61.9 38.0
Note. M: mean; SD: standard deviation.
(50–50%), between both options, which suggests that
the procreative decisions, that may be made, in the
sequence of MJD diagnosis, have constituted, for half
of the people interviewed, an argument for test tak-
ing. We found statistically significant differences in
the distribution of the answers’ frequencies to item 3
[χ2(1) = 23.273, p < .001], once a substantial percent-
age of people (86.4%; 38 out of 44) have considered
the possibility of informing their children about their
own genetic risk as one of the reasons that may de-
termine testing uptake, as opposed to 13.6% of peo-
ple (n = 6) that denied the relevance of that argu-
ment. In item 5, the majority of respondents (70.5%;
n = 31) concluded that presymptomatic testing would
permit a better mid and long-term planning of liv-
ing conditions [χ2(1) = 7.364, p<.010]. For item 10,
we found that the majority of people (93.2%; n = 41)
agreed that genetic testing will allow them to have ac-
cess to objective genetic information and would clar-
ify their doubts about their state of risk for the dis-
ease [χ2(1) = 32.818, p<.001]. Seventy-five percent
(n = 33) agreed that opting for presymptomatic diag-
nosis has got some benefits, in terms of medical assis-
tance (item 12). In contrast, 25% (n = 11) of the re-
spondents did not agree that there was any medical
benefit in knowing gene status [χ2(1) = 11, p<.010].
The better organization of the daily routine and the
resulting improvement of life quality and well-being
(item 14) seemed to be a relevant argument for
presymptomatic testing, because it attained a con-
sensus among a high proportion of people (81.8%;
n = 36), in contrast with only 18.2% (n = 8) of people
who considered that test taking wouldn’t cause any
changes in their personal life style [χ2(1) = 17.818,
p<.001]. Thirty four percent (n = 15) did not feel that
genetic testing uptake might lead to the detachment
of close people (item 16) and 65.9% (n = 29) have ac-
cepted, as possible, this consequence in interpersonal
relationships [χ2(1) = 4.455, p < .050].
1st Stage: Reliability Study
The reliability study and thus the homogene-
ity of the items were supported by the analysis of
some indicators: (1) the matrix of intercorrelations
between the items; (2) the Pearson correlation coeffi-
cient item-total; (3) the K-R coefficient for the whole
inventory and each of its sub-scales without the item;
(4) the even-odd correlations.
These criteria aimed to evaluate the contribu-
tion of each item for the internal consistency of the
PADI, but, at this stage, they were not applied to ex-
clude the less homogeneous items in relation to the
content of the inventory.
The matrix of intercorrelations showed that the
items seem to build a consistent set in which linking
dimensions among some items are drawn.
Table III summarizes the metrical character-
istics of the PADI items, relating to the above-
mentioned criteria 2 and 3. As we can see, the items
1, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15 and 16 are correlated
in a statistic significant way to the total of PADI. All
of these correlations were moderate (less than .70)
and over .20, a score pointed out by some authors
(Nunnaly, 1978; Streiner and Norman, 1989) as the
limit from which the items are considered consistent
with the construct the test aims to evaluate. The cor-
relations between items 2, 4, 11 and the total are very
low and not statistically significant; items 4 and 11 are
correlated in a negative and not significant way to the
total of the inventory.
The score of the K-R coefficient for the PADI
global score was .447, and .675 and .379, respectively,
for the perceived advantages (pros) and disadvan-
tages (cons). Bearing in mind that the majority of
investigators (Bellack and Hersen, 1976; Nunnaly,
1978; Stevens, 1992) define values between .70 and
.80 as acceptable indicators of the homogeneity of the
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Table III. Metrical Characteristics of the PADI Items
(N = 44)
K-R (without item)
Items r total-item p Pros Cons
1 .499∗∗ .002 .692
2 .040 NS .478
3 .498∗∗ .001 .624
4 − .001 NS .459
5 .505∗∗∗ .000 .605
6 − .565∗∗∗ .000 .272
7 − .409∗∗ .006 .264
8 − .448∗∗ .002 .272
9 .440∗∗ .003 .627
10 .421∗∗ .004 .651
11 − .102 NS .466
12 .317∗ .036 .674
13 .364∗ .015 .672
14 .576∗∗∗ .000 .602
15 − .537∗∗∗ .000 .283
16 − .511∗∗∗ .000 .176
K-R = .675 K-R = .379
Note. r: Pearson correlation (bilateral); NS: non-significant
correlation.
∗p < .050.
∗∗p < .010.
∗∗∗p < .001.
items that compose a scale, we can conclude that only
the K-R coefficient of the first dimension of PADI
comes closer to the inferior limit of that range. This
way, and due to our option of dealing separately with
each sub-scale, we have decided to investigate the
contribution of each item to the internal consistency
of the respective dimension.
Although item 1 does not add to the internal
consistency of the perceived advantages sub-scale, as
in its absence K-R coefficient increases from .675 to
.692, we have decided not to exclude it from the in-
ventory, owing to its significant correlation with the
total score (r = .499; p < .010).
The K-R coefficients for each question, with its
own exclusion, show that when items 2, 4 and 11
are not included the values increase above the global
score of the perceived disadvantages dimension (K-
R = .379), which means that these items do not im-
prove its internal consistency. To confirm this fact,
as we can remember, these same items (2, 4, and 11)
do not present significant correlations with the total.
These are arguments strong enough to pursue the va-
lidity studies without them.
The score of the K-R coefficient for the inven-
tory, without items 2, 4 and 11, was higher (.540) than
the one reported for the original version of 16 items
(K-R = .447). Also, the reliability of the cons dimen-
sion had a considerable improvement, without those
three items, from .379 to .816, which is a confirming
element of the homogeneity of the items that com-
pose it, if we consider that this score is higher than
the superior limit of the interval between .70 and .80,
corresponding, as we said before, to the more accept-
able coefficients. The even-odd correlation, for the
reduced version (13 items version) of the PADI, was
.439 (p < .010).
2nd Stage: Factorial Validity Study
Due to the PADI internal logical construction
and the reasons stated in the previous stage, we de-
cided to do a confirmatory factorial analysis8 with the
extraction of two factors (see Table IV), by means of
a confirmatory factorial analysis, with the method of
extraction in Principal Components followed by an
orthogonal rotation of the axis (Varimax type). The
factorial solution that was found was characterized
by two dimensions, clearly reflecting people’s cog-
nitive appraisal of the positive (advantages/pros) as-
pects (items 1, 3, 5, 9, 10, 12, 13, and 14) and negative
(disadvantages/cons) consequences (items 6, 7, 8, 15
and 16) of doing the presymptomatic diagnosis.
In their whole, the factors accounted for 43.87%
of the total variance. The first dimension was char-
acterized by 7 items and contributed with 21.33%
for the total variance; the second dimension included
5 items and accounted for the highest percentage
(22.55%) of the explained total variance. The corre-
lation between the two factorial scores was not sig-
nificant (r = − .251), which corroborate the relative
independence of the underlying dimensions.
In Table IV, are the eigenvalues, which cor-
respond to the variance of the principal compo-
nents, the communalities for each item (i.e., the pro-
portion of each item variance, represented by this
8Whereas some statisticians advise against the use of factor anal-
ysis with dichotomous variables (e.g., Gorsuch, 1983; Streiner,
1994), several other authors (Cattell, 1978; Kim and Mueller,
1978; Rummel, 1970) and extensive data show that it can be use-
ful. Drawing a parallel with dummy variable regression, Cattell
(1978) stated that a loading for 0–1 scaled variables can be in-
terpreted in two ways: as the probability of its presence (if the
loading is positive) or absence (if negative), given that the factor
exists. Also, Kim and Mueller (1978) allow the use of factorial
analysis with dichotomous data, if the underlying metric correla-
tions between the variables are moderate (.70) or lower. This last
condition was fulfilled (as we referred in the First Stage: Reliabil-
ity Study), so it was possible to perform factor analysis.
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Table IV. PADI Factorial Solution, without Items 2, 4, and 11
(N = 44)
Items Loading H2
Factor 1: Perceived advantages (pros)
1 .310 .150
3 .678 .464
5 .733 .549
9 .575 .331
10 .560 .355
12 .369 .137
13 .490 .241
14 .769 .617
Eigenvalue: 2.12, explained variance: 21.33%
Factor 2: Perceived disadvantages (Cons)
6 .720 .570
7 .805 .649
8 .761 .580
15 .691 .534
16 .779 .607
Eigenvalue: 3.58, explained variance: 22.55%
Note. h2: communalities; K.M.O.: Kaiser-Meyer-Olkin; df: de-
grees of freedom. Factorial analysis statistics: Total variance ex-
plained by the factors: 43.87%. K.M.O. = .616. Bartlett’s Test of
Sphericity = 178.326 (df = 78; p < .001).
factorial structure and explained by the retained
principal components), and the percentage of vari-
ance explained by each factor and by all of
them.
Other factorial analysis statistics guarantee the
adequacy of the factorial model to the intercorrela-
tions matrix: the Kaiser-Meyer-Olkin (KMO) mea-
sure, which value (.616) is close to the unity, and
the Bartlett’s Test of Sphericity, which refuse the hy-
pothesis of the correlations matrix being the identity
matrix with a determinant equal to one.
The PADI reduced version (13 items) was used
in the following studies.
3rd Stage: Sensitiveness to Differences of Gender,
Age and Educational Level Study
In the studied clinical sample (N = 44), the
women’s sub-group (M = 3.04; SD = 2.95) and the
men’s sub-group (M = 3.19; SD = 3.14) are equiva-
lent in what concerns the total score of the PADI
current version [t(42) = .160, p = .873]. The find-
ings are similar related to the perceived advantages
[t(42) = .896, p = .375] and the perceived disadvan-
tages [t(42) = 1.152, p = .256] of the MJD presymp-
tomatic testing.
Pearson correlations between age and each of
the PADI scores (pros, cons and total) were not
statistically significant. Also, we did not detect any
significant correlations between educational levels
(expressed in years) and PADI scores. The PADI an-
swers were not presumably influenced by differences
of gender, age or educational level.
4th Stage: Construct Validity Studies
Association Between Social Desirability and PADI
Scores
There is no statistically significance correla-
tion between the total results of PADI and SDS
(r = − .117, p = .450), and between the total SDS and
each one of the PADI dimensions, pros (r = − .058,
p = .707) and cons (r = .127, p = .413). So, we can
conclude that social approval may not have influ-
enced the answers to the PADI. This fact adds an
additional element to the PADI construct validity,
once the PADI and SDS aim to evaluate different
constructs (attitudinal objects).
Convergent Validity
We found that the Pearson correlation between
ADMQ and the total score of the PADI was not sta-
tistically significant. However, we obtained a posi-
tive and significant correlation between ADMQ and
the perceived advantages sub-scale of the PADI
(r = .377, p < .050); also, the correlation between
ADMQ total score and the negative cognitive ap-
praisal of undertaking presymptomatic testing had
statistical significance (r = − .352, p < .050). We
can infer, from this result that, as theoretically ex-
pected, the greater the confidence on doctors and
medicine in general, the higher are the scores of
the pros dimension and the lower are the values
of the cons sub-scale. Consequently, stronger im-
portance will be given to the advantages of the ge-
netic diagnosis, than to its disadvantages. In sum,
the PADI convergent validity (for both of its di-
mensions), in relation to ADMQ, was satisfactory
confirmed.
In the same way, a significant association be-
tween the PEBGDS total scoring and the PADI
cons dimension (r = − .316; p < .050) was obtained,
which reveals, as expected, that the high perceived
burden, caused by such a serious disease as MJD,
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corresponds, in the subjects at genetic risk, to a
least unfavorable evaluation of the presymptomatic
diagnosis.
There was no statistically significant relationship
between PEBGDS and the PADI perceived advan-
tages dimension (r = .104; p = .500). For this reason,
the PADI convergent validity, with reference to PE-
BGDS, was partially established, as it was confirmed
only at the level of the perceived negative aspects of
presymptomatic diagnosis.
We have also compared the total of the PTAS,
in its reduced version (Rolim and Zagalo-Cardoso, in
press) composed of 18 items, to the PADI (13 items
version), and found that there is a positive and mod-
erate correlation between them (r = .393, p<.050).
The total PTAS is also statistically associated to the
PADI first factor (r = .412; p<.010) and to the second
inventory factor (r = − .332; p<.050).
To summarize, there are important correla-
tions between the total PTAS and the total PADI
and each of its factor, though they have moder-
ate values, which suggests that the instruments have
some affinity but they do not measure the same
construct.
DISCUSSION
In this study, we developed an instrument
(the Perceived Advantages and Disadvantages of
Presymptomatic Testing Inventory, PADI) for mea-
suring perceived benefits and harms that people
at genetic risk relate to presymptomatic diagno-
sis. The instrument seems to capture relevant is-
sues concerning these two evaluative dimensions.
The items contained in the instrument appear rel-
evant to the subjects and were found to be as-
sociated, as expected, with previously validated
measures.
The interest of the PADI construction results
from the importance of the cognitive-motivational
dimension of the attitudes of subjects at genetic risk,
towards the presymptomatic diagnosis. This issue
regards the evaluation and balancing of perceived
advantages (arguments for) and disadvantages (ar-
guments against) involved in the possible course of
action (Bird, 1999; Codori and Brandt, 1994; Kessler,
1994).
The lack of empirical studies on the analysis of
the binomial equation pros/cons and of instruments
to evaluate the variable perceived advantages and
disadvantages of the presymptomatic testing, as far
as the MJD test is concerned, made us to construct
the PADI.
In the consultant’s perspective, the possibility
of presymptomatic diagnosis might bring some ad-
vantages (Rolim, 2000): the most obvious derives
from the possibility of reducing anxiety; another
has to do with the possibility of making responsi-
ble choices and taking right decisions regarding pro-
creation, academic, professional and financial areas.
There might be, however, disadvantages strictly con-
nected with the practice of genetic testing, such as
an increase in anxiety and psychological burden ow-
ing to an unfavorable result (Tibben, 2002). It is es-
sential that individuals understand these advantages
and disadvantages, prior to predictive health screen-
ing, in order to make an informed decision about
testing.
Reliability analysis showed that items 2, 4 and
11 not only do not contribute to the PADI inter-
nal consistency, but also reduce it. If we look to
the content of items 2, 4 and 11, we can understand
why they are inconsistent with the rest of the inven-
tory. A cure for the disease (item 2) is indeed irrel-
evant for the decision to take the presymptomatic
test of an incurable disease, like MJD. Most people
(61.4%; 27 out of 44) have answered item 11 (“Tak-
ing the presymptomatic test can cause too much suf-
fering, if I know that I’ll have the disease”) nega-
tively, which indicates that, for them, the option for
presymptomatic diagnosis is not a disruptive emo-
tional factor. In fact, a large amount of respondents
(93.2%) considered the test as a method with psycho-
emotional advantages, while permitting the reduc-
tion of uncertainty (item 10: “Taking the presymp-
tomatic test help to end doubts about the state of risk
concerning the disease.”). As certainty-seeking has
proved to be a decisive factor for choosing presymp-
tomatic diagnosis, it is understandable that people
may accept the test, in spite of its negative emotional
impact, in case of a carrier result (item 11). Let us
recall that the perceived emotional burden, associ-
ated with genetic disease, was correlated in a neg-
ative and significant way with the evaluation of the
genetic testing disadvantages, which suggest an im-
portant relationship between emotional and cogni-
tive processes.
As we determined by the factorial analysis, the
PADI (13 items) factorial composition is consistent
with the bidimensional approach conceived between
the perceived benefits and the perceived barriers of
the MJD presymptomatic diagnosis. That was shown
by the adequate measures of the internal consistency
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(K-R coefficients) found to the pros sub-scale and
the cons dimension (.67 and .82, respectively) of the
inventory, which allows its application in investi-
gation contexts (Nunnaly, 1978), with enlargened
samples.
The PADI seems to be a useful instrument for
the knowledge of the arguments that justify the deci-
sion about the early presymptomatic diagnosis. This
is suggested by the percentage of the total variance
accounted for by the two extracted factors (43.87%),
a satisfying value (between 40 and 50%), which is an
indicator of the adequate factor structure of a test
(Snyder et al., 1996). In fact, according to Tinsley
and Tinsley (1987) it is frequent that less than a half
of the total variance is accounted for the extracted
factors.
One of the disadvantages of self-report data is
the possible influence of a social desirability bias
(Tibben et al., 1997). Concern with the influence of
social desirability in respondents’ attitudes and opin-
ions is acceptable mainly if we bear in mind the
power of culture on the attitudes and behaviors of
individuals, in relation to certain events: “. . . a scale
built in a certain country with the help of statistic
methods, is inevitably submitted to the powerful fil-
ter of “culture”. This one moulds, in a direct or in-
direct way, the attitudes and behaviors “allowed”
in face of events and is strictly connected with the
genesis of emotions. Respondents who live in a cul-
tural context point out certain questions more of-
ten than others . . .” (Vaz Serra, 1994, p. 37). In
statistic terms, social desirability brings about a sys-
tematic error in results, being, as such, a source
of data variability (Pedhazur and Schmelkin, 1991).
The answers to the PADI do not seem to be in-
fluenced by the wish of social approval, evaluated
by the Social Desirability Scale (SDS), which also
represents an indicator of the validity of the PADI
construct.
Some studies have revealed that individuals’
opinions in relations to doctors and medicine in gen-
eral have influenced their motivation and adherence
to health care (Andrade, 1997; Marteau et al., 1992).
The more favourable are the attitudes concerning
doctors and medical practice, the more positive will
be subjects’ evaluation of the health service they
are provided with (e.g., presymptomatic diagnosis).
Thus, these studies support the proposal of a rele-
vant association between the attitudes towards doc-
tors and medicine and the perception of the advan-
tages of MJD genetic testing, on the one hand, and,
on the other hand, of an association between atti-
tudes concerning doctors and medicine and the per-
ception of costs brought about by MJD presymp-
tomatic test taking.
Additionally, certain genetic diseases, without a
treatment, have been associated with the high bur-
den (psychological, familial, marital, financial) that
these families experience (Wexler, 1979, 1984). As
Zagalo-Cardoso (1995) has shown, while comparing
the Perceived Emotional Burden Related to Genetic
Disease Scale (PEBGDS) results in three samples,
concerning one disease with preventive treatment
(phenilketonuria) and two incurable diseases (Down
syndrome and FAP-I), the perception of burden will
be the greater, the more serious will be the disease
(in this case, the last two above mentioned), in terms
of the absence of treatment/cure.
Thus, the PADI convergent validity was cor-
roborated, as it was theoretically and empirically
foreseen, by the correlation studies between the
PADI first dimension (pros) and second dimension
(cons) and the total of the Attitudes to Doctors
and Medicine Questionnaire (ADMQ). And also be-
tween perceived disadvantages and the total of the
PEBGDS.
In the genetic context, we would like to pre-
sume that the presymptomatic diagnosis can also
be a way of reduce the emotional burden related
with the stressful experience of being at risk for the
disease.
Lastly, we have shown the existence of statisti-
cally significant associations between the total of the
Presymptomatic Testing Acceptance Scale (PTAS)
and each one of the PADI factors. Bearing in mind
the convergence between the emotional and cogni-
tive attitudinal dimensions, evaluated by the PTAS
and PADI, we think they are complementing instru-
ments. Both of them may be applied at the same
time, in order to facilitate the psychosocial evalua-
tion of the candidates to presymptomatic testing of
MJD and other late genetic diseases (such as FAP-I
and HD).
Owing to the theoretical and empirical im-
portance of the separate evaluation of the subjec-
tive dimension of advantages and disadvantages of
presymptomatic tests, the adequacy of the known
factorial structure and the value of the internal con-
sistency of each sub-scale, we might consider exam-
ining pros and cons separately.
As we have mentioned earlier, the Health Belief
Model posit that performance of health-protective
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behaviors is associated with a higher perception of
advantages, which outweigh the disadvantages
associated with that action. So, we assume
that the knowledge about benefits/harms be-
liefs can predict intentions for entering genetic
testing or actual receipt of presymptomatic
diagnosis.
Limitations of the Study
In interpreting the results of our study, cer-
tain limitations should be well thought-out. First, al-
though individuals could self-refer to the study, all
of them were recruited through proactive methods,
according to pre-defined selection criteria (conve-
nience sample). Second, it could be possible that
those who agreed to participate in the research are,
in fact, a self-selected group (Bloch et al., 1989;
Codori and Brandt, 1994; Kessler, 1994; Wiggins
et al., 1992), already presenting for testing discussion
and actively considering presymptomatic diagnosis.
We know, from subsequent findings, that approxi-
mately half of the participants took active steps to-
ward learning about their genetic status and actually
undergone genetic testing.
The main limitation of our study is that the sam-
ple is not representative for the entire population at
risk for MJD. Due to the fact that MJD is a rare con-
dition, our sample is a realistic one, in spite of its
small size.
Notwithstanding these potential limitations, the
present study has important applied implications.
Implications for Practice
The real outcomes of clinical interest involve
the degree to which genetic screening actually in-
creases anxiety and symptom perseverance, during
the asymptomatic period between screening and dis-
ease onset (as a measure of the disadvantages), and
the degree to which individuals feel that genetic test-
ing allows them a better planning for assistance and
support, during the symptomatic period (perception
of positive gains).
Clinical psychologists and genetic counselors
may help those considering testing to decide whether
the potential costs are outweighed by its potential
benefits. To fulfill this requirement, they can enable
individuals to consider in detail the consequences of
taking or not taking the test and may emphasize ways
of fostering the person’s autonomy with respect to
the decision (Salkovskis et al., 1999).
The arguments to do or not to do the presymp-
tomatic diagnosis and the subjective perception of
the advantages and disadvantages of this course
of action are relevant aspects to bear in mind
in the elaboration of efficient psychological inter-
ventions, aiming at preventing emotional risks and
at helping individuals when dealing with psycho-
logical demands of the predictive testing decision-
making, as well as with the genetic diagnosis
itself.
Future Research Directions
It is our aim to conduct longitudinal work in or-
der: (1) to compare advantages/disadvantages per-
ceptions prior to screening with an actual assess-
ment of costs and benefits, after the subject has un-
dergone screening and has been found to have the
disease, and also (2) to tackle the retest reliabil-
ity and validity of our measure. In the present re-
search, the latter was unattainable, since the study
was cross-sectional, so it was impossible for us
to obtain any further data about the participants,
who were candidates to the presymptomatic test
and not yet registered in the program. Thus, we
shall attempt to conduct larger scale prospective
study among registrants to verify the results of our
study.
We hope to use our instrument with a more
broadly representative sample, in order to im-
prove its clinical use, in what concerns the de-
velopment of efficient psychological intervention
strategies.
In conclusion, we hope that PADI may con-
tribute to improve clinical answers adapted to the
people at genetic risk for this disease.
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Appendix: Perceived Advantages and
Disadvantages of Presymptomatic Testing Inventory
INSTRUCTIONS: Next, you will find some rea-
sons why you could decide taking or not taking the
presymptomatic testing.
Signal with a cross ( × ) in the square referred
as YES or NO, depending on your agreement or dis-
agreement with the reason which is presented in each
sentence.
In the end, see if you have answered all the ques-
tions.
Thank you very much for your collaboration!
Copyright 2000 by Rolim
YES NO
1. Taking the presymptomatic test helps me to
know if I should bear or not any children.
[ ] [ ]
2. Taking the presymptomatic test is not useful,
because there’s no cure for the disease.
[ ] [ ]
3. Taking the presymptomatic test enables me
to inform my children about their own risk of
developing the disease.
[ ] [ ]
4. Taking the presymptomatic test may end the
tranquility of not knowing if I’ll have the
disease.
[ ] [ ]
5. Taking the presymptomatic test may help me
to better plan my future.
[ ] [ ]
6. Taking the presymptomatic test may increase
my fear about the future.
[ ] [ ]
7. Taking the presymptomatic test may have
negative effects on the way I see myself (for
example, I may think I’m guilty about the
possible transmission of the disease to my
children).
[ ] [ ]
8. Taking the presymptomatic test may have
negative effects in my family life (for example,
increasing the worry of the wife/husband or
the anxiety of the children).
[ ] [ ]
9. Taking the presymptomatic test may help
improving psychological and social assistance
to all people that require it.
[ ] [ ]
10. Taking the presymptomatic test help to end
doubts about the state of risk concerning the
disease.
[ ] [ ]
11. Taking the presymptomatic test can cause
too much suffering, if I know that I’ll have the
disease.
[ ] [ ]
12. Taking the presymptomatic test helps to get
quick and free medical assistance more easily.
[ ] [ ]
13. Taking the presymptomatic test can lead to a
different lifestyle (for example, giving less
importance to day-by-day problems).
[ ] [ ]
14. Taking the presymptomatic test may help me
to use my free time in a more balanced way
(for example, giving more time to family, to
sport, outdoor activities).
[ ] [ ]
15. Taking the presymptomatic test may give rise
to negative attitudes from other people (for
example, employers, working colleagues,
neighbors, friends).
[ ] [ ]
16. Taking the presymptomatic test may lead to
the detachment of close people (for example,
girl/boy friend, wife/husband).
[ ] [ ]
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